| Literature DB >> 22778967 |
Theerawut Klangjareonchai1, Supanee Putadechakum, Piyamitr Sritara, Chulaporn Roongpisuthipong.
Abstract
Background. Limiting egg consumption to avoid high cholesterolemia is recommended to reduce risk of cardiovascular disease. However, recent evidences suggest that cholesterol from diet has limited influence on serum cholesterol. Objective. To assess the effect of egg consumption on lipid profiles in hyperlipidemic adults treated with lipid-lowering drugs. Material and Method. Sixty hyperlipidemic subjects, mean age of 61 years, who had been treated with lipid-lowering drugs. Every subject was assigned to consume additional 3 eggs per day with their regular diet for 12 weeks. Measurements for lipid profiles and body compositions were performed. Results. An additional consumption of 3 eggs per day for 12 weeks increased HDL-cholesterol by 2.46 ± 6.81 mg/dL (P < 0.01) and decreased LDL-cholesterol to HDL-cholesterol ratio by 0.13 ± 0.46 (P < 0.05). No significant changes were found in other lipid profiles. Body weight and body mass index were significantly increased at 12th week by 0.52 ± 1.83 kg and 0.31 ± 0.99 kg/m(2), respectively (P < 0.05). Conclusion. In hyperlipidemic adults who were treated with lipid-lowering drugs, the consumption of additional 3 eggs per day to their regular diet will increase the level of HDL-cholesterol and decrease the ratio of LDL-cholesterol to HDL-cholesterol.Entities:
Year: 2012 PMID: 22778967 PMCID: PMC3388582 DOI: 10.1155/2012/672720
Source DB: PubMed Journal: J Lipids ISSN: 2090-3049
Baseline clinical characteristics of study population.
| Variable | Values |
|---|---|
| Sex female : male | 58 : 2 |
| Age (year) | 61.8 ± 8.3 |
| Systolic blood pressure (mmHg) | 127.9 ± 9.5 |
| Diastolic blood pressure (mmHg) | 75.6 ± 9.7 |
| Body weight (kg) | 60.0 ± 7.7 |
| Body mass index (kg/m2) | 25.4 ± 3.3 |
| Lipid lowering drugs | |
| Rosuvastatin 5 mg/day | 17 (28.3%) |
| Atorvastatin 10 mg/day | 12 (20.0%) |
| Simvastatin 20 mg/day | 31 (51.7%) |
Values are mean ± SD except otherwise stated.
Mean ± SD of the body weight, BMI, and body composition.
| Baseline | 4th week | 8th week | 12th week | |
|---|---|---|---|---|
| Body weight (kg) | 60.0 ± 7.7 | 60.3 ± 8.1 | 60.3 ± 8.1 | 60.5 ± 8.1* |
| Body mass index (kg/m2) | 25.4 ± 3.3 | 25.7 ± 3.5 | 25.6 ± 3.4 | 25.8 ± 3.4* |
| Lean body weight (kg) | 40.9 ± 4.8 | 41.0 ± 4.8 | 40.5 ± 5.0 | 40.6 ± 5.2 |
| Lean body (%) | 68.7 ± 6.1 | 68.3 ± 5.6 | 67.4 ± 5.2 | 67.4 ± 5.5 |
| Body fat weight (kg) | 19.0 ± 5.3 | 19.4 ± 5.3 | 19.8 ± 4.9 | 19.9 ± 4.9 |
| Body fat (%) | 31.3 ± 6.1 | 31.7 ± 5.6 | 32.6 ± 5.2 | 32.6 ± 5.5 |
| Total body water (kg) | 30.8 ± 3.1 | 30.9 ± 3.1 | 30.5 ± 3.2 | 30.6 ± 3.3 |
| Total body water (%) | 51.7 ± 4.8 | 51.5 ± 4.4 | 50.8 ± 3.9 | 50.8 ± 4.2 |
∗ P value < 0.05 compared to baseline value.
Mean ± SD of serum lipid profiles during the study.
| Baseline | 4th week | 8th week | 12th week | |
|---|---|---|---|---|
| TC (mg/dL) | 193.4 ± 30.7 | 195.5 ± 27.7 | 194.1 ± 33.9 | 191.8 ± 28.9 |
| TG (mg/dL) | 109.5 ± 43.9 | 113.9 ± 47.4 | 116.7 ± 50.9 | 109.8 ± 42.4 |
| HDL-C (mg/dL) | 54.6 ± 12.5 | 53.9 ± 10.2 | 55.1 ± 11.3 | 57.0 ± 11.8** |
| LDL-C (mg/dL) | 108.6 ± 28.5 | 108.5 ± 24.8 | 108.0 ± 27.8 | 106.9 ± 23.8 |
| LDL-C : HDL-C | 2.1 ± 0.6 | 2.1 ± 0.6 | 2.0 ± 0.6 | 1.9 ± 0.5* |
∗ P value < 0.05 compared to baseline value.
∗∗ P value < 0.01 compared to baseline value.